• SCH772984 HCl: Applied ERK1/2 Inhibition for MAPK Pathway Re

  2026-05-21

  SCH772984 HCl, a highly potent ERK1/2 inhibitor from APExBIO, empowers precise dissection of MAPK pathway signaling in BRAF- and RAS-mutant models, with nanomolar selectivity and robust in vivo efficacy. This article delivers workflow strategies, troubleshooting tips, and cross-disciplinary insights for advanced experimental design.

• Okadaic Acid (SKU A4540): Protocols and Troubleshooting Guid

  2026-05-21

  Okadaic acid is a potent, marine-derived protein phosphatase 1 inhibitor widely used for dissecting phosphorylation-dependent signaling, apoptosis, and neurochemical regulation in research settings. This article provides technical guidance for setup, quality control, and troubleshooting of okadaic acid in cell-based and biochemical assays. It should not be used in studies where non-selective phosphatase inhibition or off-target effects would confound interpretation.

• 5-Azacytidine-Induced Dormancy Blocks Metastasis via TGF-β-S

  2026-05-20

  Singh et al. (2023) demonstrate that 5-Azacytidine, combined with retinoic acid, reprograms disseminated cancer cells into a dormant, non-proliferative state by restoring TGF-β-SMAD4 signaling. This approach robustly suppresses metastatic outgrowth, offering a mechanistic advance in metastasis prevention and highlighting new translational opportunities for DNA demethylation agents.

• Short-Scale Break-Induced Replication in Mouse Oocytes: Mech

  2026-05-20

  This study reveals that DNA double-strand breaks (DSBs) in fully grown mouse oocytes trigger a unique form of short-scale break-induced replication (ssBIR), distinct from previously described pathways. The findings highlight critical DNA repair mechanisms, with implications for genomic stability in germ cells and potential translational applications in DNA damage and repair research.

• Antibody-Based Mapping of Pseudouridine on mRNA and HIV-1 RN

  2026-05-19

  This study introduces PA-Ψ-seq, a novel antibody-based technique for high-resolution mapping of pseudouridine (Ψ) residues on both cellular and viral RNAs. The findings reveal that while specific pseudouridine synthases contribute to Ψ sites on cellular mRNA, the main enzymes responsible for Ψ addition remain undefined, particularly regarding viral transcripts—highlighting key gaps in epitranscriptomic regulation and innate immune modulation.

• URB597 (KDS-4103): Reliable FAAH Inhibition for Endocannabin

  2026-05-19

  This article addresses common laboratory challenges in endocannabinoid signaling, pain, and neuroplasticity research using URB597 (SKU A4372), a potent and selective FAAH inhibitor. Through scenario-driven Q&A, it demonstrates how URB597 from APExBIO delivers reproducibility, sensitivity, and workflow confidence—backed by quantitative data and best-practice protocols.

• Targeting Metabolic Dependencies in IDH1-Mutant AML: AG-120

  2026-05-18

  This thought-leadership article explores the latest mechanistic breakthroughs in targeting mutant IDH1-driven acute myeloid leukemia (AML). It contextualizes AG-120 (Ivosidenib) as a precision tool for translational researchers, bridging molecular insights—such as the role of CD44-mediated metabolic rewiring in therapy resistance—with actionable strategies for assay design, biomarker monitoring, and combinatorial approaches. By integrating recent discoveries and highlighting workflow optimization with AG-120, this piece guides the scientific community beyond commodity product information and into the frontier of translational oncology.

• Phase 3 Trial Validates Oral CXCR4 Antagonist for WHIM Syndr

  2026-05-18

  A recent phase 3, placebo-controlled trial demonstrated that oral mavorixafor, a selective CXCR4 antagonist, significantly improves neutrophil and lymphocyte counts and reduces infection rates in patients with WHIM syndrome. This study represents a major advance in precision therapy for a rare immunodeficiency, with important implications for CXCR4-targeted pharmacology and disease management.

• Azathramycin A: Macrolide Antibiotic for Tuberculosis Resear

  2026-05-17

  Azathramycin A is a macrolide antibiotic with proven activity against Mycobacterium tuberculosis via ribosomal inhibition. It is a key tool for modeling protein synthesis inhibition and antibiotic resistance in tuberculosis research. Its unique stability profile and solubility facilitate high-throughput screening and mechanistic studies.

• KU-60019: ATM Kinase Inhibition Refined for DNA Repair Resea

  2026-05-16

  Explore the advanced selectivity and mechanistic depth of KU-60019 as an ATM kinase inhibitor. This article uniquely bridges molecular detail with experimental strategy, offering new insights for researchers in glioma radiosensitization and DNA damage response inhibition.

• Necrostatin-1: Precision RIP1 Kinase Inhibitor for Necroptos

  2026-05-15

  Necrostatin-1 enables researchers to dissect necroptosis with unmatched specificity, supporting both mechanistic discovery and translational studies in inflammation and tissue injury. This guide delivers optimized protocols, troubleshooting strategies, and insights from the latest research to maximize reproducibility and data quality.

• Verapamil HCl: Precision L-Type Calcium Channel Blocker Work

  2026-05-15

  Verapamil HCl is a gold-standard L-type calcium channel blocker that empowers researchers to dissect calcium dynamics, modulate apoptosis, and attenuate inflammation in both cellular and in vivo models. This guide details applied workflows, troubleshooting strategies, and experimental optimizations—bridging high-impact myeloma and arthritis research with robust, reproducible protocols.

• H-89: cAMP-Dependent Protein Kinase Inhibitor for Cell Signa

  2026-05-14

  H-89 from APExBIO empowers precise modulation of cAMP signaling in advanced cell-based assays, enabling nuanced dissection of PKA-driven events in osteogenesis and metabolic regulation. This guide translates new findings on Wnt-induced glycolytic rewiring into actionable protocols, troubleshooting strategies, and workflow enhancements for reproducible research.

• Lycium barbarum Polysaccharide Counters Muscle Atrophy via A

  2026-05-14

  This study reveals that Lycium barbarum polysaccharide (LBP) alleviates skeletal muscle atrophy induced by a high-fat diet through activation of AMPK/PINK1/Parkin-mediated mitophagy. The findings highlight key mechanistic links between energy metabolism regulation and mitochondrial quality control, offering new directions for metabolic disease research.

• Fangchinoline Restores TFEB-Driven Lysosomal Biogenesis in I

  2026-05-13

  Cheng et al. reveal that fangchinoline reverses influenza-induced lysosomal dysfunction by activating TFEB and its downstream gene network, thereby obstructing H1N1 infection at the entry stage. This work positions lysosomal biogenesis modulation as a promising host-directed antiviral strategy.

11540 records 2/770 page Previous Next 12345 下5页 Last page